State of Arizona (AZ)
Emmanuel KatsanisUniversity of Arizona Health Center, Professor
Department of Pediatrics
A novel anti-cancer vaccine has been developed in the laboratory (called Chaperone Rich Cell Lysate or CRCL) that has been shown to be effective against a variety of tumors in mice. CRCL has a more pronounced immunologic effect per unit of protein than any of the individual HSP vaccines currently used in clinical trials. We have found that it can stimulate potent tumor-specific T cell responses against a variety of tumors in mice. Furthermore it has intrinsic adjuvant activity capable of stimulating both natural killer (NK) cells and dendritic cells (DC). Moreover, it can protect these cells from regulatory T cell immunosuppression. Since tumor-derived CRCL vaccines are effective against a wide range of tumor types in mice, we have embarked on in vitro human studies to confirm our findings. We have demonstrated that CRCL can be used effectively to pulse DCs and to generate specific T cells against human cancer. This personalized vaccine is a promising approach for active cancer immunotherapy and merits further study in humans.
http://www.u.arizona.edu/~ekatsani/university.html
Christos Katsanos
Arizona State University, Assistant Professor
Dept. of Kinesiology and Center for Metabolic Biology
Christos.Katsanos(at)asu.edu
http://www.asu.edu/clas/kines/Profiles/Katsanos/katsanos.htm